Drug Profile
Research programme: neurological disorder therapies - MedDay
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator MedDay Pharmaceuticals
- Developer Assistance Publique Hopitaux de Paris; Commissariat a l'Energie Atomique; MedDay Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Neurological-disorders in France
- 06 Mar 2017 Early research in Neurological disorders in France (unspecified route) before March (9212638; Medday Pharmaceuticals Pipeline,